Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida...

ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Tumour microenvironment and circulating biomarkers predict response to...

Dr David Braun - Yale School of Medicine, New Haven, USA

Tumour microenvironment and circulating biomarkers predict response to immunotherapy in advanced RCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial...

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )

ASCO 2025: Latest updates in mRCC

Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier...

ASCO 2025: Latest updates in mRCC ( Dr Michael Serzan, Dr Guillermo De Velasco, Dr Alessandro Rametta and Dr Javier Puente )

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible...

Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus ipilimumab vs gemcitabine-carboplatin in cisplatin-ineligible metastatic urothelial carcinoma ( Dr Michiel Simon van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

New MOAs in prostate cancer treatment - what’s next?

Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini

New MOAs in prostate cancer treatment - what’s next? ( Dr Joaquin Mateo, Dr Andrew Parsonson and Dr Capucine Baldini )

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

QoL maintained with sasanlimab plus BCG in high-risk, BCG-naive NMIBC ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA

QoL improvements ID'd in phase 3 ARANOTE trial for mHSPC ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )

BCG combined with mitomycin offers improved adjuvant treatment regimen for high...

Prof Dickon Hayne - University of Western Australia, Perth, Australia

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC ( Prof Dickon Hayne - University of Western Australia, Perth, Australia )

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received...

Prof Thomas Powles - Barts Cancer Institute, London, England

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab ( Prof Thomas Powles - Barts Cancer Institute, London, England )

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

Prof Thomas Powles - Barts Cancer Institute, London, England

Sasanlimab BCG combo improves outcomes in high-risk NMIBC ( Prof Thomas Powles - Barts Cancer Institute, London, England )

More from ecancer